GA is a severe and progressive form of age-related macular degeneration (AMD) often leading to significant visual impairment or legal blindness. 

IZERVAY (avacincaptad pegol) is approved to treat those with an intact fovea and threatened central vision. Approval was based on the GATHER1 and GATHER2 global trials, where IZERVAY significantly slowed GA lesion growth, by 35% and 18% respectively over 12 months. Sustained efficacy was observed over two years, with benefits evident as early as six months. The treatment was well tolerated, with fewer than 2% of participants discontinuing due to adverse events.